On May 20, Abivax S.A. rose 5.18% in regular trading, trading at $119.645/share, with trading volume of $76.20 million.

On the news front, Abivax S.A. is scheduled to release its earnings report on May 25 before market open. Although quarterly revenue is expected to decline sharply by 88.78% year-over-year, bullish institutional sentiment dominates. Most sell-side analysts maintain a Buy rating on the company, with target prices set above the current trading range. Last quarter, Abivax reported revenue of EUR 440,000 with a gross margin of 100%, while net loss attributable to shareholders was EUR 81.96 million, with adjusted EPS of -EUR 1.14. The market is closely monitoring how the company's financing and royalty arrangements will affect its expense structure and cash flow trajectory going forward.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases. Its lead candidate, obefazimod, is currently in Phase 3 clinical trials for moderately to severely active ulcerative colitis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)